Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Nat Med ; 5(6): 662-8, 1999 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-10371505

RESUMEN

Resistance to chemotherapy is a principal problem in the treatment of small cell lung cancer (SCLC). We show here that SCLC is surrounded by an extensive stroma of extracellular matrix (ECM) at both primary and metastatic sites. Adhesion of SCLC cells to ECM enhances tumorigenicity and confers resistance to chemotherapeutic agents as a result of beta1 integrin-stimulated tyrosine kinase activation suppressing chemotherapy-induced apoptosis. SCLC may create a specialized microenvironment, and the survival of cells bound to ECM could explain the partial responses and local recurrence of SCLC often seen clinically after chemotherapy. Strategies based on blocking beta1 integrin-mediated survival signals may represent a new therapeutic approach to improve the response to chemotherapy in SCLC.


Asunto(s)
Apoptosis/fisiología , Carcinoma de Células Pequeñas/metabolismo , Carcinoma de Células Pequeñas/patología , Proteínas de la Matriz Extracelular/metabolismo , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patología , Clorometilcetonas de Aminoácidos/farmacología , Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Bradiquinina/farmacología , Carcinoma de Células Pequeñas/tratamiento farmacológico , Caspasa 3 , Inhibidores de Caspasas , Caspasas/metabolismo , Adhesión Celular/efectos de los fármacos , División Celular/fisiología , Colágeno/metabolismo , Ciclofosfamida/farmacología , Doxorrubicina/farmacología , Resistencia a Antineoplásicos , Inhibidores Enzimáticos/farmacología , Etopósido/farmacología , Fibronectinas/metabolismo , Galanina/farmacología , Humanos , Integrina beta1/metabolismo , Laminina/metabolismo , Neoplasias Pulmonares/tratamiento farmacológico , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Proteínas Tirosina Quinasas/metabolismo , Tenascina/metabolismo , Células Tumorales Cultivadas , Tirfostinos/farmacología
2.
Int J Biochem Cell Biol ; 130: 105881, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33181315

RESUMEN

Galectin-3 is a beta-galactoside-binding mammalian lectin and part of the 15 member galectin family that are evolutionarily highly conserved. It is the only chimeric protein with a C-terminal carbohydrate recognition domain (CRD) linked to a proline, glycine, and tyrosine rich additional N-terminal domain. Galectin-3 binds several cell surface glycoproteins via its CRD domain as well as undergoing oligomerization, via binding at the N-terminal or the CRD, resulting in the formation of a galectin-3 lattice on the cell surface. The galectin-3 lattice has been regarded as being a crucial mechanism whereby extracellular galectin-3 modulates cellular signalling by prolonging retention time or retarding lateral movement of cell surface receptors in the plasma membrane. As such galectin-3 can regulate various cellular functions such as diffusion, compartmentalization and endocytosis of plasma membrane glycoproteins and glycolipids and the functionality of membrane receptors. In multiple models of organ fibrosis, it has been demonstrated that galectin-3 is potently pro-fibrotic and modulates the activity of fibroblasts and macrophages in chronically inflamed organs. Increased galectin-3 expression also activates myofibroblasts resulting in scar formation and may therefore impact common fibrotic pathways leading to fibrosis in multiple organs. Over the last decade there has been a marked increase in the scientific literature investigating galectin-3 in a range of fibrotic diseases as well as the clinical development of new galectin-3 inhibitors. In this review we will examine the role of galectin-3 in fibrosis, the therapeutic strategies for inhibiting galectin-3 in fibrotic disease and the clinical landscape to date.


Asunto(s)
Endocitosis , Fibrosis/tratamiento farmacológico , Galectinas/antagonistas & inhibidores , Inflamación/prevención & control , Animales , Proteínas Sanguíneas/antagonistas & inhibidores , Fibrosis/metabolismo , Fibrosis/patología , Galectinas/metabolismo , Humanos , Inflamación/metabolismo , Inflamación/patología
3.
Cell Death Differ ; 13(10): 1776-88, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16410797

RESUMEN

The emergence of resistance to chemotherapy remains a principle problem in the treatment of small-cell lung cancer (SCLC). We demonstrate that extracellular matrix (ECM) activates phosphatidyl inositol 3-kinase (PI3-kinase) signaling in SCLC cells and prevents etoposide-induced caspase-3 activation and subsequent apoptosis in a beta1 integrin/PI3-kinase-dependent manner. Crucially we show that etoposide and radiation induce G2/M cell cycle arrest in SCLC cells prior to apoptosis and that ECM prevents this by overriding the upregulation of p21(Cip1/WAF1) and p27(Kip1) and the downregulation of cyclins E, A and B. These effects are abrogated by pharmacological and genetic inhibition of PI3-kinase signaling. Importantly we show that chemoprotection is not mediated by altered SCLC cell proliferation or DNA repair. Thus, ECM via beta1 integrin-mediated PI3-kinase activation overrides treatment-induced cell cycle arrest and apoptosis, allowing SCLC cells to survive with persistent DNA damage, providing a model to account for the emergence of acquired drug resistance.


Asunto(s)
Apoptosis , Carcinoma de Células Pequeñas/metabolismo , Carcinoma de Células Pequeñas/patología , Ciclo Celular , Matriz Extracelular/metabolismo , Integrina beta1/metabolismo , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patología , Fosfatidilinositol 3-Quinasas/metabolismo , Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Apoptosis/efectos de la radiación , Carcinoma de Células Pequeñas/terapia , Adhesión Celular , Línea Celular Tumoral , Daño del ADN , Etopósido/farmacología , Glucógeno Sintasa Quinasa 3/metabolismo , Glucógeno Sintasa Quinasa 3 beta , Humanos , Laminina/metabolismo , Neoplasias Pulmonares/terapia , Mutación , Fosforilación , Proteínas Tirosina Quinasas/metabolismo , Proteínas Proto-Oncogénicas c-akt/genética , Proteínas Proto-Oncogénicas c-akt/metabolismo , Vanadatos/farmacología
4.
Int J Radiat Biol ; 83(11-12): 733-41, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17852559

RESUMEN

PURPOSE: Lung cancer is the leading cause of cancer deaths in the developed world. Small cell lung cancer (SCLC) has the worst prognosis due to the emergence of resistance to chemotherapy. This article will review recent work that has defined mechanisms of chemo-resistance focusing on the role of integrins. RESULTS: SCLC is surrounded by an extensive stroma of extracellular matrix (ECM) and high levels of expression correlate with poor prognosis. ECM protects SCLC cells against chemotherapy-induced cell death by activating beta1 integrins leading to activation of phosphoinositide-3-OH kinase (PI3-kinase), which prevents etoposide-induced caspase-3 activation and subsequent apoptosis. Engagement of ECM prevents etoposide and radiation induced G2/M cell cycle arrest in SCLC cells by blocking the up-regulation of p21Cip1/WAF1 and p27Kip1 and the down-regulation of cyclins E, A and B. These effects are abrogated by pharmacological and genetic inhibition of PI3-kinase signalling. CONCLUSIONS: Thus, ECM via beta1 integrin-mediated PI3-kinase activation allows SCLC cells to survive treatment induced cell cycle arrest and apoptosis with persistent DNA damage, providing a model to account for the emergence of acquired drug resistance. Novel therapeutic strategies may therefore be directed at inhibiting integrin-mediated cell survival signals improving response rates and cure in this devastating cancer.


Asunto(s)
Carcinoma de Células Pequeñas/tratamiento farmacológico , Resistencia a Antineoplásicos/fisiología , Matriz Extracelular/fisiología , Neoplasias Pulmonares/tratamiento farmacológico , Carcinoma de Células Pequeñas/patología , Carcinoma de Células Pequeñas/fisiopatología , Carcinoma de Células Pequeñas/radioterapia , Supervivencia Celular , Humanos , Integrinas/fisiología , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/fisiopatología , Neoplasias Pulmonares/radioterapia , Modelos Biológicos , Pronóstico , Transducción de Señal
5.
Aliment Pharmacol Ther ; 45(3): 443-454, 2017 02.
Artículo en Inglés | MEDLINE | ID: mdl-27896824

RESUMEN

BACKGROUND: Acute liver failure (ALF) is associated with significant morbidity and mortality. Studies have implicated the immune response, especially monocyte/macrophages as being important in dictating outcome. AIM: To investigate changes in the circulating monocytes and other immune cells serially in patients with ALF, relate these with cytokine concentrations, monocyte gene expression and patient outcome. METHODS: In a prospective case-control study in the Scottish Liver Transplant Unit, Royal Infirmary Edinburgh, 35 consecutive patients admitted with paracetamol-induced liver failure (POD-ALF), 10 patients with non-paracetamol causes of ALF and 16 controls were recruited. The peripheral blood monocyte phenotype was analysed by flow cytometry, circulating cytokines quantified by protein array and monocyte gene expression array performed and related to outcome. RESULTS: On admission, patients with worst outcomes after POD-ALF had a significant monocytopenia, characterised by reduced classical and expanded intermediate monocyte population. This was associated with reduced circulating lymphocytes and natural killer cells, peripheral cytokine patterns suggestive of a 'cytokine storm' and increased concentrations of cytokines associated with monocyte egress from the bone marrow. Gene expression array did not differentiate patient outcome. At day 4, there was no significant difference in monocyte, lymphocyte or natural killer cells between survivors and the patients with adverse outcomes. CONCLUSIONS: Severe paracetamol liver failure is associated with profound changes in the peripheral blood compartment, particularly in monocytes, related with worse outcomes. This is not seen in patients with non-paracetamol-induced liver failure. Significant monocytopenia on admission may allow earlier clarification of prognosis, and it highlights a potential target for therapeutic intervention.


Asunto(s)
Acetaminofén/efectos adversos , Analgésicos no Narcóticos/efectos adversos , Enfermedad Hepática Inducida por Sustancias y Drogas/diagnóstico , Leucopenia/inducido químicamente , Leucopenia/diagnóstico , Fallo Hepático Agudo/inducido químicamente , Monocitos/patología , Adulto , Estudios de Casos y Controles , Enfermedad Hepática Inducida por Sustancias y Drogas/sangre , Enfermedad Hepática Inducida por Sustancias y Drogas/complicaciones , Enfermedad Hepática Inducida por Sustancias y Drogas/mortalidad , Citocinas/metabolismo , Femenino , Humanos , Leucopenia/complicaciones , Leucopenia/mortalidad , Fallo Hepático Agudo/sangre , Fallo Hepático Agudo/diagnóstico , Fallo Hepático Agudo/mortalidad , Trasplante de Hígado/efectos adversos , Trasplante de Hígado/mortalidad , Masculino , Monocitos/efectos de los fármacos , Pronóstico , Análisis de Supervivencia , Resultado del Tratamiento
6.
Nat Commun ; 8(1): 1118, 2017 10 24.
Artículo en Inglés | MEDLINE | ID: mdl-29061963

RESUMEN

Mesenchymal cells expressing platelet-derived growth factor receptor beta (PDGFRß) are known to be important in fibrosis of organs such as the liver and kidney. Here we show that PDGFRß+ cells contribute to skeletal muscle and cardiac fibrosis via a mechanism that depends on αv integrins. Mice in which αv integrin is depleted in PDGFRß+ cells are protected from cardiotoxin and laceration-induced skeletal muscle fibrosis and angiotensin II-induced cardiac fibrosis. In addition, a small-molecule inhibitor of αv integrins attenuates fibrosis, even when pre-established, in both skeletal and cardiac muscle, and improves skeletal muscle function. αv integrin blockade also reduces TGFß activation in primary human skeletal muscle and cardiac PDGFRß+ cells, suggesting that αv integrin inhibitors may be effective for the treatment and prevention of a broad range of muscle fibroses.


Asunto(s)
Integrina alfaV/metabolismo , Músculo Esquelético/patología , Miocardio/patología , Receptor beta de Factor de Crecimiento Derivado de Plaquetas/genética , Animales , Apoptosis , Movimiento Celular , Células Cultivadas , Colágeno/metabolismo , Fibrosis , Genotipo , Humanos , Masculino , Células Madre Mesenquimatosas/citología , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Receptor beta de Factor de Crecimiento Derivado de Plaquetas/metabolismo , Proteínas Recombinantes/metabolismo
7.
Trends Pharmacol Sci ; 15(4): 119-23, 1994 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-7912461

RESUMEN

The proliferation of receptor subtypes based on differences in amino acid sequence does not necessarily coincide with functional differences. The number of alpha 2-adrenoceptor subtypes, as defined by ligand-binding and molecular studies, has been increasing in the past few years, which suggests the possibility of distinct physiological and pathological pathways that could be targeted by new selective drugs. However, the evidence from functional studies has been less convincing. This could be due to the lack of sufficiently selective ligands or to the similarity between the activated state of receptor subtypes. Species differences and the local receptor environment are also important determinants of the pharmacological profile of a particular subtype. The pharmacology of the putative subtypes of alpha 2-adrenoceptors and their function are discussed in this review by Alison MacKinnon, Mike Spedding and Christine Brown.


Asunto(s)
Receptores Adrenérgicos alfa/clasificación , Receptores Adrenérgicos alfa/fisiología , Antagonistas Adrenérgicos alfa/farmacología , Animales , Clonación Molecular , Humanos , Biología Molecular , Receptores Adrenérgicos alfa/genética , Sistemas de Mensajero Secundario/fisiología
8.
J Med Chem ; 34(2): 705-17, 1991 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-1671705

RESUMEN

Analogues of the potent alpha 2-adrenoceptor antagonist (8aR,12aS,13aS)-5,8,8a,9,10,11,12,12a,13,13a- decahydro-3-methoxy-12-(methylsulfonyl)- 6H-isoquino[2,1-g][1,6]naphthyridine (1b) were prepared and evaluated for alpha 1- and alpha 2-adrenoceptor affinity. Affinity for alpha 2-adrenoceptors was assessed by displacement of [3H]yohimbine from rat cerebral cortical membranes and although 1b and close structural analogues demonstrated high affinity, none were selective for the alpha 2A or alpha 2B subtypes reputedly present in this tissue. All of the high affinity alpha 2-adrenoceptor ligands were, however, selective with respect to [3H]prazosin (alpha 1) binding. Affinity for [3H]yohimbine-labeled alpha 2-adrenoceptors was found to be highly dependent on the stereochemistry of the tetracyclic system. The 8a beta,12a alpha,13a alpha diastereomer of 1 (56) had moderate affinity for alpha 2-adrenoceptors while the 8a beta,12a beta,13a alpha diastereomer (55) had very low affinity. The affinity and selectivity of these agents for alpha 2-adrenoceptors was found to correspond to that observed for several isomeric yohimbine analogues which have similar relative and absolute stereochemistries. Deviation from the structure of 1 by opening the B ring, changing the position of the sulfonamide nitrogen, or changing the attachment of the D ring led to a dramatic decrease in alpha 2-adrenoceptor affinity. High binding affinity was found to correlate with functional antagonism in the guinea pig ileum. The reversal of clonidine-induced mydriasis in the rat was used to assess bioavailability and indicated that 1b was a potent alpha 2-adrenoceptor antagonist in vivo.


Asunto(s)
Antagonistas Adrenérgicos alfa/síntesis química , Naftiridinas/síntesis química , Antagonistas Adrenérgicos alfa/metabolismo , Antagonistas Adrenérgicos alfa/farmacología , Animales , Fenómenos Químicos , Química , Cobayas , Masculino , Músculo Liso/efectos de los fármacos , Naftiridinas/metabolismo , Naftiridinas/farmacología , Ratas , Ratas Endogámicas , Receptores Adrenérgicos alfa/efectos de los fármacos , Receptores Adrenérgicos alfa/metabolismo , Estereoisomerismo , Relación Estructura-Actividad
9.
J Med Chem ; 33(2): 596-600, 1990 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-2153820

RESUMEN

A series of 2-(tetrahydroisoquinolin-2-ylmethyl)- and 2-(isoindolin-2-ylmethyl)imidazolines were prepared and tested for alpha 1- and alpha 2-adrenoceptor affinity with radioligand binding. Several compounds, 5-fluoro-(5h), 5-chloro-(5j), 5,8-dimethoxy- (5r), and 5,8-dimethoxy- (5r),1-methyl- (5s) 2-(tetrahydroisoquinolin-2- ylmethyl)imidazoline, were found to be selective alpha 2-adrenoceptor ligands on the basis of displacement of [3H]yohimbine from rat cerebral cortical membranes. One compound, 2-[(8-chloro tetrahydroisoquinolin-2-yl)methyl]imidazoline (5m), showed a 36-fold difference in affinity for the [3H]idazoxan-labeled alpha 2-adrenoceptor relative to the [3H]yohimbine-labeled site, which may be evidence for alpha 2-adrenoceptor subtypes.


Asunto(s)
Imidazoles/metabolismo , Indoles/metabolismo , Isoquinolinas/metabolismo , Receptores Adrenérgicos alfa/metabolismo , Animales , Sitios de Unión , Unión Competitiva , Corteza Cerebral , Fenómenos Químicos , Química Física , Dioxanos/metabolismo , Idazoxan , Imidazoles/síntesis química , Técnicas In Vitro , Indoles/síntesis química , Isoquinolinas/síntesis química , Ligandos , Prazosina/metabolismo , Ensayo de Unión Radioligante , Ratas , Relación Estructura-Actividad , Yohimbina/metabolismo
10.
J Med Chem ; 33(2): 633-41, 1990 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-2153822

RESUMEN

A number of 1,9-alkano-bridged 2,3,4,5-tetrahydro-1H-3-benzazepines were prepared and evaluated for 5-HT1A receptor and alpha 2-adrenoceptor affinity by using radioligand receptor binding techniques. Several compounds displayed 5-HT1A receptor affinity comparable to, or greater than, the known 5-HT1A ligand buspirone. The highest affinity 5-HT1A receptor ligands were N-alkyl-, N-allyl-5-chloro-, and 5-methoxy-1,2,3,4,8,9,10,10a-octahydronaphth[1,8-cd]azapines (4c, 4m, 4n), which had pKi values of 7.9-8.1. The S enantiomer of 4c had a higher affinity for the 5-HT1A receptor than the corresponding R isomer (pKi of 8.2 for (S)-4c vs 7.7 for (R)-4c). These compounds had a relatively low affinity for the alpha 2-adrenoceptor (pKi of 7 or less). On the other hand, the closely related 5-chloro-2-methyl-2,3,4,8,9,9a-hexahydro-1H-indeno[1,7-cd]azepine (3b) had high affinity for both the alpha 2-adrenoceptor (pKi = 8.1) and 5-HT1A receptor (pKi = 7.6). These results indicate that the two receptors may share common recognition sites.


Asunto(s)
Benzazepinas/síntesis química , Receptores Adrenérgicos alfa/metabolismo , Receptores de Serotonina/metabolismo , Animales , Benzazepinas/metabolismo , Corteza Cerebral/metabolismo , Fenómenos Químicos , Química , Química Física , Técnicas In Vitro , Ensayo de Unión Radioligante , Ratas , Ratas Endogámicas , Relación Estructura-Actividad , Termodinámica
11.
Br J Pharmacol ; 109(2): 371-8, 1993 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8102928

RESUMEN

1. The alpha 2-adrenoceptors on human platelets and neonatal rat lung were characterized with the agonist and antagonist ligands [3H]-adrenaline and [3H]-RS-15385-197 respectively. A correlation of affinities for 3H-antagonist binding showed the receptors to be of the alpha 2A-(platelet) and alpha 2B-(neonatal rat lung) adrenoceptor subtypes, whereas a correlation of affinities for 3H-agonist binding showed the receptors to have similar characteristics (r = 0.88). 2. NaCl (100 mM) had no effect on [3H]-RS-15385-197 binding in the human platelet, but increased the density of sites labelled with [3H]-RS-15385-197 in neonatal rat lung by 52%. NaCl increased the density of sites labelled by [3H]-adrenaline in neonatal rat lung, but there was a consequent 3.5 fold decrease in affinity. In the human platelet, no specific [3H]-adrenaline binding was observed in the presence of 100 mM NaCl. 3. In the neonatal rat lung, NaCl had no significant effect on the affinity of prazosin for [3H]-RS-15385-197 binding; however, imiloxan affinity was increased 13 fold. The affinity of the catecholamines, adrenaline and noradrenaline was significantly decreased, whereas the imidazolines, oxymetazoline and UK-14,304 were much less affected. The affinity of prazosin and imiloxan for [3H]-adrenaline binding was significantly increased in the presence of 10 and 100 mM NaCl. Conversely, the affinity of adrenaline and noradrenaline was decreased in the presence of NaCl, and there was no change in the affinity of the imidazoline agonists. 4. In the human platelet, NaCl had no effect on the affinity of prazosin for [3H]-RS-15385-197 binding but the affinity of imiloxan was significantly increased. NaCl significantly decreased the affinity of the catecholamines adrenaline and noradrenaline, whereas the affinity of UK-14,304 and oxymatazoline was much less affected. Competition experiments with [3H]-adrenaline in the presence of NaCl in platelets were difficult to characterize as there was no specific binding under these conditions.5. The results show that both the alpha2A- and alpha2B-adrenoceptor subtypes are allosterically regulated by Na+, but only the alpha2B-subtype showed a significant increase in density. Interestingly, there is a differential regulation of imidazoline (unchanged) and catecholamine (decreased affinity) agonist interactions with these subtypes. Na+ may therefore critically affect receptor subtype selectivity of drugs. The implications for receptor subclassification are discussed.


Asunto(s)
Agonistas alfa-Adrenérgicos/metabolismo , Antagonistas Adrenérgicos alfa/metabolismo , Receptores Adrenérgicos alfa/metabolismo , Sodio/metabolismo , Animales , Animales Recién Nacidos/fisiología , Plaquetas/efectos de los fármacos , Plaquetas/metabolismo , Membrana Celular/metabolismo , Epinefrina/metabolismo , Femenino , Humanos , Técnicas In Vitro , Isoquinolinas/farmacología , Pulmón/efectos de los fármacos , Pulmón/metabolismo , Masculino , Naftiridinas/farmacología , Ratas , Ratas Sprague-Dawley
12.
Br J Pharmacol ; 109(2): 437-42, 1993 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8395288

RESUMEN

1. A high density of [3H]-PK 11195 binding sites was present in gerbil cortical membranes (Bmax [3H]-PK 11195 1360 +/- 71 fmol mg-1 protein) in comparison to rat cortical membranes (254 +/- 21 fmol mg-1 protein). This effect was species-specific as similar findings were obtained with hippocampal membranes (Bmax 1430 +/- 111 fmol mg-1 protein in gerbil, compared to 196 +/- 31 in rat). 2. RO 5-4864, also a peripheral type benzodiazepine compound, displayed low affinity for the [3H]-PK 11195 site in the gerbil (pKi 6.57 +/- 0.02 and 6.70 +/- 0.12 in hippocampus and cortex respectively) compared to rat (pKi 8.16 +/- 0.07 and 8.48 +/- 0.02). Central benzodiazepine compounds, diazepam and flunitrazepam, also displayed this trend. 3. RO 5-4864 displaced [3H]-PK 11195 binding from gerbil and rat cortical membranes through a competitive interaction with Hill slopes close to unity. In both tissues, saturation isotherms of [3H]-PK 11195 binding indicated that the presence of RO 5-4864 caused changes in Kd without any effect on Bmax. In kinetic experiments, the presence of RO 5-4864 failed to modify the rate of dissociation of [3H]-PK 11195 from equilibrium in both rat and gerbil cortical membranes. 4. Forebrain ischaemia in the Mongolian gerbil (5 min bilateral carotid artery occlusion) with 7 days recovery caused a significant (P<0.05) decrease in the density of hippocampal 5-HTlA binding sites labelled by [3H]-8-OH-DPAT (Bmax control, 393 +/- 33 fmol mg-1 protein; ischaemic, 289 +/- 21 fmol mg protein)and an increase (P<0.01) in [3H]-PK 11195 binding sites (Bmax control, 1430 +/- 111 fmol mg-1 protein; ischaemic, 2160 +/- 170 fmol mg-1 protein). Ischaemia and recovery had no effect on the affinity of either ligand.5. Autoradiography experiments in gerbil brain sections revealed that the ischaemia-induced increase in[3H]-PK 11195 binding was consistent and significant in the CA, subfield on the hippocampus (control,152 +/- 42 fmol mg-1 tissue; ischaemic, 314 +/- 43 fmol mg-1 tissue).


Asunto(s)
8-Hidroxi-2-(di-n-propilamino)tetralin/farmacocinética , Isquemia Encefálica/metabolismo , Isoquinolinas/farmacocinética , Prosencéfalo/metabolismo , Receptores de GABA-A/metabolismo , Animales , Autorradiografía , Benzodiazepinas/farmacología , Benzodiazepinonas/farmacología , Unión Competitiva/efectos de los fármacos , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Convulsivantes/farmacología , Gerbillinae , Hipocampo/citología , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Técnicas In Vitro , Masculino , Membranas/efectos de los fármacos , Membranas/metabolismo , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Prosencéfalo/citología , Ratas , Receptores de GABA-A/efectos de los fármacos
13.
Br J Pharmacol ; 116(2): 1729-36, 1995 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-8528552

RESUMEN

1. RS-45041-190 (4-chloro-2-(imidazolin-2-yl)isoindoline) is an I2 imidazoline receptor ligand with the highest affinity and selectivity so far described; [3H]-RS-45041-190 has a tritium atom attached to the 7-position on the isoindoline ring. 2. [3H]-RS-45041-190 binding to rat kidney membranes was saturable (Bmax = 223.1 +/- 18.4 fmol mg-1 protein) and of high affinity (Kd = 2.71 +/- 0.59 nM). Kinetic studies revealed that the binding was rapid and reversible, with [3H]-RS-45041-190 interacting with two sites or two affinity states. 3. Competition studies showed that 60-70% of [3H]-RS-45041-190 binding (1 nM) was specifically to imidazoline binding sites of the I2 subtype, characterized by high affinity for idazoxan (pIC50 7.85 +/- 0.03) and cirazoline (pIC50 8.16 +/- 0.05). The remaining 30-40% was displaced specifically by the monoamine oxidase A inhibitors, clorgyline and pargyline. 4. alpha 1- and alpha 2-adrenoceptor, I1 imidazoline, histamine, 5-hydroxytryptamine or dopamine receptor ligands had low affinity suggesting that [3H]-RS-45041-190 did not label receptors of these classes. 5. In autoradiography studies, [3H]-RS-45041-190 labelled discrete regions of rat brain corresponding to the distribution of I2 subtypes, notably the subfornical organ, arcuate nucleus, interpeduncular nucleus, medial habenular nucleus and lateral mammillary nucleus, and additional sites in the locus coeruleus, dorsal raphe and dorsomedial hypothalamic nucleus. 6. [3H]-RS-45041-190 therefore labels I2 receptors with high affinity, and an additional site which has high affinity for some monoamine oxidase inhibitors.


Asunto(s)
Antagonistas Adrenérgicos alfa/farmacología , Dioxanos/farmacología , Imidazoles/farmacología , Indoles/farmacología , Riñón/efectos de los fármacos , Receptores de Droga/efectos de los fármacos , Animales , Autorradiografía , Unión Competitiva , Relación Dosis-Respuesta a Droga , Idazoxan , Receptores de Imidazolina , Isoindoles , Masculino , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley , Factores de Tiempo
14.
Br J Pharmacol ; 98(4): 1143-50, 1989 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-2558757

RESUMEN

1. [3H]-idazoxan labels a single population of high affinity sites (Kd 2.26 +/- 0.02 nM; Bmax 372 +/- 25 fmol mg-1 protein) in hamster adipocyte membranes. In the presence of 1 microM yohimbine to preclude binding to alpha 2-adrenoceptors, the density of [3H]-idazoxan binding sites was reduced (287 +/- 18 fmol mg-1 protein) without an apparent decrease in the affinity (Kd 2.19 +/- 0.24 nM) of the radioligand. 2. Displacement studies indicate that alpha-adrenoceptor ligands with an imidazoline side chain completely inhibit [3H]-idazoxan binding to hamster adipocyte membranes; in contrast, the alpha 2-adrenoceptor antagonists yohimbine, rauwolscine, BDF 6143 and phentolamine inhibited only 20-30% of the specific binding with affinity values consistent with an interaction at alpha 2-adrenoceptors. 3. The low potency of noradrenaline and adrenaline in displacing [3H]-idazoxan binding to the second site on hamster adipocyte membranes indicates that it is unlikely that this site is a type of adrenoceptor. 4. These results suggest that [3H]-idazoxan binds with high affinity to two sites in hamster adipocytes: an alpha 2-adrenoceptor and a non-adrenoceptor imidazoline site.


Asunto(s)
Tejido Adiposo/metabolismo , Dioxanos/metabolismo , Dioxinas/metabolismo , Receptores Adrenérgicos alfa/metabolismo , Receptores de Droga/metabolismo , Tejido Adiposo/citología , Animales , Unión Competitiva , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Cricetinae , Idazoxan , Receptores de Imidazolina , Técnicas In Vitro , Cinética , Masculino , Mesocricetus , Ratas , Ratas Endogámicas
15.
Br J Pharmacol ; 115(6): 1103-9, 1995 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-7582509

RESUMEN

1. [3H]-lifarizine bound saturably and reversibly to an apparently homogeneous class of high affinity sites in rat cerebrocortical membranes (Kd = 10.7 +/- 2.9 nM; Bmax = 5.10 +/- 1.43 pmol mg-1 protein). 2. The binding of [3H]-lifarizine was unaffected by sodium channel toxins binding to site 1 (tetrodotoxin), site 3 (alpha-scorpion venom) or site 5 (brevetoxin), Furthermore, lifarizine at concentrations up to 10 microM had no effect on [3H]-saxitoxin (STX) binding to toxin site 1. Lifarizine displaced [3H]-batrachotoxinin-A 20-alpha-benzoate (BTX) binding with moderate affinity (pIC50 7.31 +/- 0.24) indicating an interaction with toxin site 2. However, lifarizine accelerated the dissociation of [3H]-BTX and decreased both the affinity and density of sites labelled by [3H]-BTX, suggesting an allosteric interaction with toxin site 2. 3. The binding of [3H]-lifarizine was voltage-sensitive, binding to membranes with higher affinity than to synaptosomes (pIC50 for cold lifarizine = 7.99 +/- 0.09 in membranes and 6.68 +/- 0.14 in synaptosomes). Depolarization of synaptosomes with 130 mM KCl increased the affinity of lifarizine almost 10 fold (pIC50 = 7.86 +/- 0.25). This suggests that lifarizine binds selectively to inactivated sodium channels which predominate both in the membrane preparation and in the depolarized synaptosomal preparation. 4. There was negligible [3H]-lifarizine and [3H]-BTX binding to solubilized sodium channels, although [3H]-STX binding was retained under these conditions. 5. The potencies of a series of compounds in displacing [3H]-lifarizine from rat cerebrocortical membranes correlated well with their affinities for inactivated sodium channels estimated from whole-cell voltage clamp studies in the mouse neuroblastoma cell line, NIE-115 (r=0.96).6. These results show that [3H]-lifarizine is a high affinity ligand for neuronal sodium channels which potently and selectively labels a site, allosterically linked to toxin binding site 2, associated within activated sodium channels.


Asunto(s)
Imidazoles/farmacología , Piperazinas/farmacología , Canales de Sodio/efectos de los fármacos , Animales , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Relación Dosis-Respuesta a Droga , Imidazoles/metabolismo , Masculino , Técnicas de Placa-Clamp , Piperazinas/metabolismo , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley , Saxitoxina/farmacología , Canales de Sodio/metabolismo , Factores de Tiempo
16.
Br J Pharmacol ; 106(4): 1011-8, 1992 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-1327384

RESUMEN

1. RS-15385-197 is the most potent and selective alpha 2-adrenoceptor antagonist available. We have used [3H]-RS-15385-197 to define alpha 2-adrenoceptor subtypes. The binding of [3H]-RS-15385-197 to membranes of rat cerebral cortex, rat neonatal lung and human platelets was reversible, saturable and of high affinity. Saturation experiments indicated that [3H]-RS-15385-197 bound to a single population of sites in all 3 tissues with high affinity (0.08-0.14 nM). The density of sites labelled by [3H]-RS-15385-197 was greater in the cortex (275 fmol mg-1 protein) than in the neonate lung (174 fmol mg-1 protein) and human platelet (170 fmol mg-1 protein). The density of sites labelled with [3H]-RS-15385-197 in the cortex was significantly greater than that labelled with [3H]-yohimbine (121 fmol mg-1 protein). 2. The selective alpha 2-adrenoceptor antagonists, idazoxan, yohimbine, rauwolscine and WY 26703 displaced [3H]-RS-15385-197 binding to rat cerebral cortex in a simple manner with Hill slopes close to unity. The affinities derived for these antagonists against [3H]-RS-15385-197 were similar to the values obtained for the displacement of [3H]-yohimbine indicating the alpha 2-adrenoceptor nature of the binding site. 3. alpha 2A-Adrenoceptor selective compounds, oxymetazoline and BRL 44409, showed high affinity for [3H]-RS-15385-197 binding in the human platelet and lower affinity in the neonate lung, while the alpha 2B-selective compounds, prazosin and imiloxan, showed high affinity for [3H]-RS-15385-197 binding in the neonate lung.This suggests that [3H]-RS-15385-197 labels both alpha2A- and alpha2B-adrenoceptor subtypes.4. Prazosin and methysergide inhibited the binding of [3H]-RS-15385-197 in the rat cerebral cortex in a simple manner consistent with an interaction at a single site. Although oxymetazoline inhibited [H]-RS- 15385-197 with a Hill slope significantly different from unity, the slope was increased to unity in the presence of Gpp(NH)p, suggesting an agonist-like interaction.5. The site labelled by [3H]-RS-15385-197 in the rat cortex shows high affinity for oxymetazoline and low affinity for prazosin which could be taken as evidence for classifying the site as an alpha2A-subtype.However, the affinities of yohimbine, rauwolscine and oxymetazoline at this site do not correspond to the population of sites in the human platelet. Yohimbine and rauwolscine were 20 fold selective for the platelet alph2A-subtype, whereas phentolamine was 2 fold and imiloxan was 10 fold selective for the cortex subtype. Indeed although the site showed some similarities with the alpha2A-subtype, the highest degree of homology was observed between this site and the rat submaxillary gland and the RG20 clone,tentatively called the alpha2D-adrenoceptor subtype. We propose that the alpha2-adrenoceptor in the rat cortex may therefore correspond to the putative alpha2D-subtype of the adrenoceptor.


Asunto(s)
Isoquinolinas/metabolismo , Naftiridinas/metabolismo , Receptores Adrenérgicos alfa/clasificación , Animales , Plaquetas/metabolismo , Corteza Cerebral/metabolismo , Humanos , Técnicas In Vitro , Pulmón/metabolismo , Masculino , Ensayo de Unión Radioligante , Ratas , Ratas Endogámicas , Receptores Adrenérgicos alfa/metabolismo , Tritio , Yohimbina/metabolismo
17.
Br J Pharmacol ; 99(4): 803-9, 1990 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-1972896

RESUMEN

1. The binding of [3H]-yohimbine and [3H]-idazoxan to rat cortex and hippocampus is rapid, reversible and of high affinity. Saturation data indicate that a single population of binding sites exist for [3H]-yohimbine in the cortex (Bmax 121 +/- 10 fmol mg-1, protein; Kd 5.2 +/- 0.9 nM) and hippocampus (Bmax 72 +/- 6 fmol mg-1 protein; Kd 5.8 +/- 0.7 nM). [3H]-idazoxan labels one site in the cortex (Bmax 87 +/- 8 fmol mg-1 protein; Kd 4.1 +/- 0.9 nM) and hippocampus (Bmax 30 +/- 6 fmol mg-1 protein; Kd 3.5 +/- 0.5 nM), when 3 microM phentolamine is used to define non-specific binding. A second distinct [3H]-idazoxan binding site (Bmax 110 +/- 21 fmol mg-1 protein; Kd 3.6 +/- 0.07 nM) is identified in rat cortex if 0.3 microM cirazoline is used to define non-specific binding and 3 microM yohimbine is included to prevent binding to alpha 2-adrenoceptors. 2. Displacement studies indicate that the alpha 1-adrenoceptor antagonist prazosin and the 5-HT1 ligands 8-OH-DPAT, RU 24969 and methysergide differentiate [3H]-yohimbine binding into two components; a high and low affinity site. In contrast the displacement of [3H]-idazoxan by each ligand was monophasic. 3. The affinities of 8-OH-DPAT, RU 24969 and methysergide determined against [3H]-idazoxan binding to the cortex and hippocampus correlate significantly with the binding site displaying low affinity for prazosin and previously designated alpha 2A. In contrast, a poor correlation exists for the high affinity site for prazosin designated alpha 2B. 4. [3H]-idazoxan, in the presence of 3 microM yohimbine, labels a site that displays high affinity towards cirazoline, naphazoline and guanabenz, but low affinity towards clonidine, p-aminoclonidine, adrenaline, noradrenaline and the alpha 2-adrenoceptor antagonists yohimbine, rauwolscine, WY 26703 and BDF 6143. 5. The results of this study indicate that [3H]-yohimbine labels two sites; the alpha 2A- and alpha 2B-adrenoceptors whereas [3H]-idazoxan labels an alpha 2-adrenoceptor with a profile consistent with the alpha 2A-adrenoceptor subtype. In addition, [3H]-idazoxan labels an imidazoline binding site in the rat cortex that is pharmacologically distinct from alpha 2-adrenoceptors. The low affinity of clonidine and p-aminoclonidine indicates that the imidazoline-like binding site in rat cortex is different from the site labelled by [3H]-clonidine and [3H]-p-aminoclonidine in human, rat and bovine brain stem, providing evidence of potential heterogeneity within this class of binding sites.


Asunto(s)
Química Encefálica/efectos de los fármacos , Imidazoles/farmacología , Receptores Adrenérgicos alfa/efectos de los fármacos , Receptores de Droga/efectos de los fármacos , 8-Hidroxi-2-(di-n-propilamino)tetralin , Agonistas alfa-Adrenérgicos/farmacología , Animales , Bovinos , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Dioxanos/metabolismo , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Humanos , Idazoxan , Receptores de Imidazolina , Técnicas In Vitro , Indoles/metabolismo , Cinética , Masculino , Metisergida/metabolismo , Ratas , Ratas Endogámicas , Receptores Adrenérgicos alfa/metabolismo , Receptores de Droga/metabolismo , Tetrahidronaftalenos/metabolismo , Yohimbina/metabolismo
18.
Br J Pharmacol ; 99(3): 481-6, 1990 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-1970497

RESUMEN

1. Saturation experiments indicated that [3H]-yohimbine binding was specific, saturable and labelled a single population of sites in rat cerebral cortex (Kd 5.3 +/- 0.9 nM, Bmax 121 +/- 10 fmol mg-1 protein) and human platelets (Kd 0.7 +/- 0.1 nM, Bmax 152 +/- 10 fmol mg-1 protein). 2. The alpha 2-adrenoceptor antagonists, yohimbine, rauwolscine, WY 26703, idazoxan and BDF 6143 displaced [3H]-yohimbine binding to each tissue in a simple manner, with high affinity and Hill slopes close to unity. 3. The alpha 1-adrenoceptor agonist, oxymetazoline and the antagonist prazosin inhibited the binding of [3H]-yohimbine to rat in a complex manner consistent with an interaction at more than one site. However, indoramin and WB 4101 only appeared to interact with one site. In contrast, in human platelets, all antagonists gave rise to monophasic displacement curves with Hill slopes close to unity suggesting a single site of interaction. 4. The 5-hydroxytryptamine (5-HT) receptor ligands, 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), RU 24969, and methysergide inhibited the binding of [3H]-yohimbine to rat cortex with high and low affinity, consistent with an interaction with two populations of binding sites. However, inhibition of [3H]-yohimbine binding to human platelets suggested a single site of interaction. The low affinity of 5-HT, 5-carboxyamidotryptamine (5-CT) and dipropyl-5-CT indicated that [3H]-yohimbine was not labelling a 5-HT1-like site in rat cortex. 5. The ability of 8-OH-DPAT, RU 24969 and methysergide in addition to prazosin and oxymetazoline to differentiate [3H]-yohimbine binding provides additional pharmacological evidence for heterogeneity within rat cortical alpha 2-adrenoceptors. However, if the two sites in rat cortex that are differentiated by the 5-HT ligands represent (alpha 2A- and alpha 2B-adrenoceptor subtypes as defined by prazosin and oxymetazoline, then they do not correspond to the population of sites in human platelets. As receptor classification should be linked to affinity of drugs rather than tissue distribution, the current classification of alpha 2-adrenoceptor subtypes does not appear to be satisfactory.


Asunto(s)
Plaquetas/metabolismo , Corteza Cerebral/metabolismo , Indoles/farmacología , Metisergida/farmacología , Naftalenos/farmacología , Receptores Adrenérgicos alfa/efectos de los fármacos , Tetrahidronaftalenos/farmacología , 8-Hidroxi-2-(di-n-propilamino)tetralin , Agonistas alfa-Adrenérgicos/metabolismo , Agonistas alfa-Adrenérgicos/farmacología , Antagonistas Adrenérgicos alfa/metabolismo , Antagonistas Adrenérgicos alfa/farmacología , Animales , Unión Competitiva/efectos de los fármacos , Plaquetas/efectos de los fármacos , Corteza Cerebral/efectos de los fármacos , Guanosina Trifosfato/farmacología , Técnicas In Vitro , Cinética , Masculino , Oximetazolina/farmacología , Prazosina/farmacología , Ratas , Ratas Endogámicas , Receptores Adrenérgicos alfa/metabolismo , Especificidad de la Especie , Yohimbina/metabolismo
19.
Br J Pharmacol ; 116(2): 1737-44, 1995 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-8528553

RESUMEN

1. RS-45041-190 (4-chloro-2-(imidazolin-2-yl)isoindoline) showed high affinity for I2 imidazoline receptors labelled by [3H]-idazoxan in rat (pKi = 8.66 +/- 0.09), rabbit (pKi = 9.37 +/- 0.07), dog (pKi = 9.32 +/- 0.18) and baboon kidney (pKi = 8.85 +/- 0.12), but had very low affinity for alpha 2-adrenoceptors in rat cerebral cortex (pKi = 5.7 +/- 0.09). 2. RS-45041-190 showed low affinity for other adrenoceptors, dopamine, 5-hydroxytryptamine, and muscarinic receptors and dihydropyridine binding sites (selectivity ratio > 1000). 3. RS-45041-190 showed moderate potency for the inhibition of monoamine oxidase A in vitro (pIC50 = 6.12), but had much lower potency for monoamine oxidase B (pIC50 = 4.47), neither of which equated with its affinity for I2 receptors. 4. RS-45041-190 (0.001 to 3 mg kg-1, i.v. and 1 ng-50 micrograms i.c.v.) had only small, transient effects on blood pressure and heart rate in anaesthetized rats. In conscious rats, RS-45041-190 had no effect on body core temperature or tail skin temperature (1 mg kg-1, s.c.) or on activity or rotarod performance (10 mg kg-1, i.p.). There were also no effects on barbiturate sleeping time in mice after doses of 1-10 mg kg-1, i.p. 5. RS-45041-190 (10 and 25 mg kg-1, i.p.) significantly increased food consumption in rats for up to 4 h after dosing, but unlike idazoxan (10 mg kg-1, i.p.) did not increase water consumption. RS-45041-190 is therefore a selective, high-affinity ligand at I2 imidazoline receptors and its hyperphagic effect may suggest a role for I2 imidazoline receptors in the modulation of appetite.However, in the absence of a selective agonist it is unclear whether this ligand is an agonist or an antagonist at I2 receptors.


Asunto(s)
Antagonistas Adrenérgicos alfa/farmacología , Dioxanos/farmacología , Imidazoles/farmacología , Riñón/efectos de los fármacos , Receptores de Droga/efectos de los fármacos , Animales , Apetito/efectos de los fármacos , Unión Competitiva , Presión Sanguínea/efectos de los fármacos , Perros , Relación Dosis-Respuesta a Droga , Ingestión de Alimentos/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Idazoxan , Receptores de Imidazolina , Masculino , Ratones , Conejos , Ratas , Ratas Sprague-Dawley , Factores de Tiempo
20.
Br J Pharmacol ; 108(2): 526-33, 1993 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-8095421

RESUMEN

1. RS-15385-197, a highly potent and selective alpha 2-adrenoceptor antagonist, was examined in a variety of in vitro and in vivo functional tests to assess the selectivity of its interaction with central noradrenergic neurones in the rat. 2. In hypothalamic slices, RS-15385-197 was potent in augmenting K(+)-evoked release of [3H]-noradrenaline, with an EC50 of 9 nM. Idazoxan and yohimbine showed 100 fold less activity. This was due to its antagonist action at presynaptic alpha 2-adrenoceptors, as RS-15385-197 (10 microM), did not directly release [3H]-noradrenaline from cortical slices unlike reserpine (10 microM), and did not inhibit noradrenaline re-uptake into cortical synaptosomes. 3. In vivo, RS-15385-197 (0.5 mg kg-1, p.o.) increased levels of 3-methoxy-4-hydroxy-phenylglycol (MHPG) in the cerebral cortex without modifying levels of 5-hydroxyindoleacetic acid (5-HIAA). This dose, but not a lower dose (0.1 mg kg-1, p.o.) caused beta-adrenoceptor down-regulation in the cortex when administered once daily for 14 days whereas 5-HT2 receptor number was unaltered, indicating a selective effect on noradrenergic transmission. 4. Selective depletion of cortical 5-HT by administration of p-chlorophenylalanine (PCPA; 100 mg kg-1, i.p. for 14 days) or 5,7-dihydroxytryptamine (5,7-DHT; 150 micrograms i.c.v.) prevented the beta-adrenoceptor down-regulation caused by RS-15385-197, indicating that a tonic 5-hydroxytryptaminergic input was required for it to elicit beta-adrenoceptor down-regulation. It was not possible to prevent the loss of activity of RS-15385-197 in these 5-HT-depleted animals by co-administration with the 5-HT1A partial agonist, 8-hydroxy-n-dipropyl aminotetralin (8-OH-DPAT, 0.3 mg kg-1, i.p. twice daily for final 3 days).5. At a dose (1 mg kg-1, p.o.) which completely prevented the hypoactivity produced by clonidine(0.1 mgkg-1, p.o.), RS-15385-197 did not affect behavioural stereotypy induced by 8-OH-DPAT(0.3 mg kg-1, s.c.). Similarly, following chronic dosing with the racemate, RS-15385-196 (3 mg kg-1,p.o., once daily for 14 days), there was no effect on the behavioural and hypothermic response to 8-OH-DPAT (0.5 mg kg-1, s.c.). Therefore, RS-1 5385-197 was selective for central alpha2-adrenoceptors over 5-HT1A receptors in in vivo functional tests.6. Thus, RS-15385-197 was highly selective in interacting with central noradrenergic neurones in the rat in vitro and in vivo. It is therefore currently the agent of choice for investigations of the role of alpha 2-adrenoceptors in the CNS.


Asunto(s)
Antagonistas Adrenérgicos alfa/farmacología , Corteza Cerebral/efectos de los fármacos , Hipotálamo/efectos de los fármacos , Isoquinolinas/farmacología , Naftiridinas/farmacología , Norepinefrina/fisiología , Animales , Conducta Animal/efectos de los fármacos , Temperatura Corporal/efectos de los fármacos , Corteza Cerebral/metabolismo , Clonidina/antagonistas & inhibidores , Regulación hacia Abajo/efectos de los fármacos , Hipotálamo/metabolismo , Técnicas In Vitro , Masculino , Norepinefrina/metabolismo , Potasio/farmacología , Ratas , Ratas Sprague-Dawley , Serotonina/farmacología , Estereoisomerismo , Sinaptosomas/efectos de los fármacos , Sinaptosomas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA